Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse PersonsColleen F. Kelley, Renu Singh, Maribel Acevedo-Quiñones et al.|New England Journal of Medicine|2024Cited by 260
Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083Todd T. Brown, Raphael J. Landovitz, Ricardo Vasconcelos et al.|Clinical Infectious Diseases|2025Cited by 2